Highlights

  • LTR Pharma shares surged 20.00% to AUD 0.51 during afternoon trade on 11 June 2026.
  • The company executed a binding term sheet with Strive Pharmacy, securing exclusive US pharmacy fulfilment rights for ROXUS.
  • The partnership provides access to a multi-state pharmacy platform licensed across all 50 US states.
  • The agreement supports LTR Pharma’s planned multi-channel commercialisation strategy in the United States.
  • The announcement represents a significant launch-readiness milestone ahead of planned commercial launch activities.

LTR Pharma Ltd (ASX:LTP) attracted strong investor attention during the afternoon session on 11 June 2026, with shares climbing 20.00% to AUD 0.51 after the company announced a key commercialisation milestone for its erectile dysfunction treatment, ROXUS.

The market reaction followed news that LTR Pharma had executed a binding term sheet with Strive Specialties Inc. (Strive Pharmacy), establishing an exclusive US pharmacy fulfilment arrangement for ROXUS. The agreement provides the infrastructure required to support future supply and distribution of the product in the United States and forms an important component of the company's broader commercial launch strategy.

Today's share price gain adds to a favourable longer-term performance, with LTR Pharma shares up 59.38% over the past 12 months. Investors appeared encouraged by the latest progress as the company continues advancing preparations for entry into the world's largest erectile dysfunction treatment market.

About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company focused on developing and commercialising treatments through its proprietary intranasal drug delivery platform.

The company specialises in therapies designed to address unmet medical needs by providing rapid-onset treatment options through nasal spray formulations. Its lead products include SPONTAN and ROXUS, both developed for the treatment of erectile dysfunction.

According to the company, these products are designed to achieve onset of action within 10 minutes or less, offering an alternative to traditional oral treatment options.

Beyond men's health, LTR Pharma is also advancing OROFLOW, an intranasal therapy under development for oesophageal motility disorders, expanding the potential applications of its delivery technology.

The company has already commercialised its technology in Australia and continues to pursue opportunities in the United States and other international markets.

Exclusive US Partnership Strengthens Commercial Readiness

The centrepiece of the latest announcement is the execution of a binding term sheet with Strive Pharmacy, a US-based personalised medicine and 503A pharmacy provider.

The agreement grants Strive exclusive US pharmacy fulfilment rights for ROXUS, subject to ongoing performance requirements.

Under the proposed arrangement, LTR Pharma will remain the product owner, intellectual property holder and formulation supplier, while Strive will provide pharmacy fulfilment services across the United States.

The partnership establishes the pharmacy infrastructure required to dispense ROXUS prescriptions through the company's planned US commercial channels.

Management described the agreement as a key launch-readiness milestone that advances preparations for commercial launch activities.

Supporting Entry Into the World's Largest Erectile Dysfunction Market

The United States represents one of the most significant markets globally for erectile dysfunction treatments.

The latest agreement is designed to support LTR Pharma's planned entry into this market by ensuring the necessary pharmacy fulfilment infrastructure is in place before launch.

According to the company, ROXUS will be supplied through a multi-channel commercialisation strategy that incorporates telehealth providers, pharmacy fulfilment services and healthcare provider networks.

This approach is intended to provide multiple pathways through which patients can access the treatment.

By securing fulfilment capabilities ahead of launch, the company aims to reduce operational execution risk while improving future patient access opportunities.

Why ROXUS Is Different

ROXUS is LTR Pharma's rapid-acting intranasal treatment for erectile dysfunction.

Unlike traditional oral phosphodiesterase type 5 (PDE5) inhibitor therapies, ROXUS is administered through the nasal cavity using the company's proprietary delivery technology.

The company believes the intranasal approach aligns with growing consumer demand for on-demand treatment options.

ROXUS is expected to be supplied in the United States through the Section 503A personalised medicine pathway, which allows treatment to be prepared and dispensed through licensed pharmacy networks.

Management views the product's delivery mechanism as an important differentiator within a highly established therapeutic category.

Strive Pharmacy Brings National Infrastructure

A major aspect of the partnership is the scale of Strive Pharmacy's existing infrastructure.

Strive operates a multi-state pharmacy platform with operations across five US states and holds pharmacy licences covering all 50 states.

The company provides compounding, packaging, fulfilment and shipping services for prescription medicines across the country.

Its infrastructure supports healthcare providers, clinics and telehealth operators through established pharmacy fulfilment networks.

Under the proposed arrangement, Strive will be responsible for preparation, fulfilment, shipping and related quality and supply chain activities associated with ROXUS.

For LTR Pharma, this provides access to an established operational network rather than requiring the development of new fulfilment capabilities from the ground up.

Additional Access to Healthcare Networks

Beyond fulfilment services, the partnership also provides access to broader healthcare provider and clinic networks.

Management indicated that these networks may support future commercial expansion initiatives once launch activities commence.

Healthcare provider engagement is often a key component of product commercialisation strategies, particularly within therapeutic categories where physician involvement remains important.

The ability to leverage existing relationships within provider and telehealth channels may support future patient acquisition efforts.

Combined with pharmacy fulfilment capabilities, the arrangement is intended to strengthen the company's commercial infrastructure ahead of launch.

Key Terms of the Arrangement

The agreement currently exists in the form of a binding term sheet rather than a completed supply and fulfilment agreement.

The parties intend to negotiate and finalise definitive agreements within 30 days of the effective date, with the option for a single 30-day extension by mutual agreement.

If definitive agreements are not executed within the specified period, the broader arrangement will terminate, although certain binding provisions will remain in effect.

The exclusivity arrangement grants Strive sole US 503A pharmacy and fulfilment rights for ROXUS during the agreement term.

The initial term will run for two years from commercial launch, with annual automatic renewals unless either party elects not to continue.

Commercial launch remains subject to completion of technology transfer activities, pharmacy onboarding and other launch-readiness requirements.

Part of a Broader US Expansion Strategy

The latest announcement represents another step in LTR Pharma's broader strategy to expand internationally.

The company has previously highlighted the United States as a key growth market given its size and established demand for erectile dysfunction treatments.

Securing pharmacy fulfilment infrastructure is one of several components required before commercial launch can occur.

Management noted that the agreement complements ongoing patient acquisition initiatives and market access programs currently being pursued by the company.

The arrangement is intended to support a scalable launch model capable of reaching patients through multiple channels.

As launch preparation activities continue, investors are likely to monitor additional developments relating to market access, provider engagement and commercial readiness.

Management Highlights Importance of the Milestone

Executive Chairman Lee Rodne described the agreement as a material advancement of the company's US commercialisation strategy.

He noted that securing an experienced national pharmacy fulfilment partner provides important operational infrastructure ahead of launch.

Management believes the arrangement reduces launch execution risk while supporting future patient access opportunities.

Strive Pharmacy President and Co-Founder Michael Walker also expressed support for the partnership, highlighting ROXUS as an innovative addition to the men's health category and noting alignment with the company's focus on personalised medicine.

The parties will now work toward finalising definitive agreements and progressing launch-readiness activities.

What This Means for Investors?

LTR Pharma's latest announcement appears to have resonated with investors because it addresses a critical component of commercial launch preparation in the United States. The exclusive fulfilment partnership with Strive Pharmacy provides access to national pharmacy infrastructure, healthcare provider networks and operational capabilities necessary to support future distribution of ROXUS.

While the arrangement remains subject to final definitive agreements and commercial launch conditions, the announcement represents tangible progress toward entry into the US market. The combination of launch-readiness advancement, expanded patient access opportunities and reduced operational risk likely contributed to the stock's 20% rise during afternoon trading.